Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. [electronic resource]
Producer: 20180725Description: 104-112 p. digitalISSN:- 1365-2516
- Adolescent
- Adult
- Area Under Curve
- Blood Coagulation Factor Inhibitors -- blood
- Dose-Response Relationship, Drug
- Double-Blind Method
- Factor IX -- adverse effects
- Half-Life
- Headache -- etiology
- Hemophilia B -- drug therapy
- Hemorrhage -- prevention & control
- Humans
- Male
- ROC Curve
- Recombinant Proteins -- pharmacokinetics
- Severity of Illness Index
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.